<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="805">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04679428</url>
  </required_header>
  <id_info>
    <org_study_id>Golnik_Covid-19</org_study_id>
    <nct_id>NCT04679428</nct_id>
  </id_info>
  <brief_title>Immunological Characteristics of COVID-19 Patients</brief_title>
  <official_title>Immunological Characteristics of COVID-19 Patients and Determination of Neutralizing Antibodies Against SARS-CoV-2 Virus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University Clinic of Pulmonary and Allergic Diseases Golnik</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Chemistry, Slovenia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University Clinic of Pulmonary and Allergic Diseases Golnik</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will look at the immunological characteristics of COVID-19 patients and determine&#xD;
      neutralizing antibodies against SARS-CoV-2 virus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The immunogram (quantitative TBNK immunophenotipisation) will be performed by flow cytometry,&#xD;
      the antibody response will be determined by IVD ELISa.&#xD;
&#xD;
      Clinical biochemical and immunochemical (ECLIA) tests (including IL-6) will be performed on&#xD;
      Cobas analyzers. Hemogram with differential blood picture will be performed with a hematology&#xD;
      analyzer Sysmex XN 3100, examination of blood smears with CellaVision system or. microscope.&#xD;
      Coagulation tests will be performed on BCS XP analyzers.&#xD;
&#xD;
      An in-house system for the analysis of SARS-CoV-2 virus fusion inhibitors on human cells will&#xD;
      be used to detect the ability of antibodies from patients' serum to neutralize the virus and&#xD;
      thus potential protection against re-infection. The system is quantitative, meaning that the&#xD;
      titer of such antibodies could be determined, and thus the potential level of protection&#xD;
      would be evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2020</start_date>
  <completion_date type="Anticipated">May 7, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 7, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Immunological changes during and after COVID-19 infection</measure>
    <time_frame>July 2022</time_frame>
    <description>Correlation between TBNK dynamic and increase of neutralising antibodies</description>
  </primary_outcome>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Covid19</condition>
  <eligibility>
    <study_pop>
      <textblock>
        COVID-19 patients recruited at University Clinic of Pulmonary and Allergic Diseases Golnik.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Provide written consent before being included in the essay.&#xD;
&#xD;
        Positive cases of COVID-19 (based on polymerase chain reaction or positive antigen test for&#xD;
        SARS-CoV-2).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients who are unable to give consent or who are unable to follow up will be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Korošec, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of the Laboratory for Clinical Immunology and Molecular Genetics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Korošec, PhD</last_name>
    <phone>042569432</phone>
    <phone_ext>+386</phone_ext>
    <email>peter.korosec@klinika-golnik.si</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gregor Ostanek</last_name>
    <phone>42569500</phone>
    <phone_ext>+386</phone_ext>
    <email>gregor.ostanek@klinika-golnik.si</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Clinic of Respiratory and Allergic Diseases Golnik</name>
      <address>
        <city>Golnik</city>
        <zip>4204</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Korošec, PhD</last_name>
      <phone>4 25 69 432</phone>
      <phone_ext>+386</phone_ext>
      <email>peter.korosec@klinika-golnik.si</email>
    </contact>
    <investigator>
      <last_name>Peter Korošec, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barbara Bitežnik, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aleš Rozman, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matjaž Fležar, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katarina Osolnik, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Petra Svetina, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vesna Nikolić, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Kopač, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tomaž Hafner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tina Jerič, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nina Frelih, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mojca Bizjak, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristina Cerk Porenta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rok Lombar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katja Adamič, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katja Mohorčič, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sanja Grm Zupan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tanja Šubic, M.Sc. Nursing</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Izidor Kern, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mile Kovačevič, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gregor Vlačić, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pika Meško Brguljan, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Urška Bidovec Stojkovič, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matija Rijavec, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana Koren, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ajda Demšar, MsC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 21, 2020</study_first_submitted>
  <study_first_submitted_qc>December 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2020</study_first_posted>
  <last_update_submitted>December 21, 2020</last_update_submitted>
  <last_update_submitted_qc>December 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University Clinic of Pulmonary and Allergic Diseases Golnik</investigator_affiliation>
    <investigator_full_name>Peter Korošec</investigator_full_name>
    <investigator_title>Assoc Prof Peter Korošec, BSc (Biol), PhD</investigator_title>
  </responsible_party>
  <keyword>Covid-19</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>immunology</keyword>
  <keyword>TBNK Cells</keyword>
  <keyword>neutralizing antibodies</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

